Close Menu

Sam Tsimikas, Michael Davidson, and others

Sep 18, 2018

Boston Heart Diagnostics, a subsidiary of Eurofins Scientific, appointed five members to its scientific advisory board. They are Sam Tsimikas; Michael Davidson; Peter Reaven; Dennis Goodman; and H. Robert Superko. Tsimikas is a cardiologist at the University of California, San Diego specializing in lipoprotein. Davidson is a cardiologist at the University of Chicago with a specialty in omega-3 fatty acid metabolism and clinical use, while Reaven is at the University of Arizona where he researches insulin resistance and diabetes. Goodman specializes in integrative medicine at New York University, and Superko is a founder of Berkeley Heart Lab and a specialist in lipoprotein subfractionization.

More Like This

Jan 26, 2021

AMP COVID Response Steering Committee: Frederick Nolte, Karen Kaul, and More

The Association for Molecular Pathology announced the creation of the AMP COVID Response Steering Committee to coordinate the organization's efforts during the pandemic. Eight people were named to the committee, including Frederick Nolte, the chair of the committee and the former chair of the AMP Infectious Diseases Subdivision, who is the professor and vice-chair for laboratory medicine at Medical University of South Carolina, and Karen Kaul, a former AMP president and a clinical professor of pathology at University of Chicago's Pritzker School of Medicine.

Other appointees are Eric Konnick, the co-chair of the AMP Professional Relations Committee and assistant professor and associate director of the Genetics and Solid Tumor Laboratory at University of Washington; Jordan Laser, the other co-chair of the AMP Professional Relations Committee and an associate professor of pathology and laboratory medicine at Hofstra; Timothy O'Leary, a former AMP president and the former chief research and development officer at the Department of Veterans Affairs; Antonia Sepulveda, AMP president and professor and chair of the George Washington School of Medicine's department of pathology; Karen Weck, the immediate past president of AMP and a professor of pathology and laboratory medicine at University of North Carolina Chapel Hill; and Donna Wolk, the chair of AMP's Infectious Diseases Subdivision and division director of molecular and microbial diagnostics and development for the Diagnostic Medicine Institute at Geisinger.

Jan 25, 2021

OncoDNA: Bernard Courtieu, Jean-Pol Detiffe, Eduardo Bravo

OncoDNA has appointed Bernard Courtieu as CEO and Jean-Pol Detiffe as chief strategic and innovation officer of the firm. Courtieu previously served as IntegraGen, which was acquired by OncoDNA last July. Prior to IntegraGen, Courtieu served as VP at Gemini Consulting.

Eduardo Bravo, who currently serves as interim CEO of OncoDNA, will remain a consultant to the firm's board. 

Jan 21, 2021

QuantuMDx: Diran Guiliguian

QuantuMDx has appointed Diran Guiliguian as chief commercial officer. He was most recently head of central lab solutions for Europe, Middle East, and Africa at Siemens Healthineers, where he led the introduction of the firm's COVID-19 testing solutions. He previously managed the diagnostics business for Southern Europe for the company.

Jan 19, 2021

Circulogene: Stephen Unger

Circulogene has appointed Stephen Unger as its CFO. Unger most recently served as a managing director of equity research at Needham & Company. He has also served as CFO of Quotient, which completed a successful initial public offering in 2014. 

Jan 19, 2021

HTG Molecular Diagnostics: Timothy Johnson, Ann Hanham

HTG Molecular Diagnostics has announced that Timothy Johnson has resigned as executive chairman and as a member of HTG's board of directors. Ann Hanham will remain as the firm's led independent director. 

Jan 19, 2021

Foundation Medicine: Cindy Perettie

Foundation Medicine, a Roche subsidiary, announced Cindy Perettie would be transitioning to Roche Diagnostics to lead the molecular lab solutions business, effective April 6. Perettie has been the CEO of Foundation Medicine since 2019 and previously served as senior VP with product strategy responsibility for the global oncology portfolio at Roche and Genentech. She also led global portfolio management for IVAX Pharmaceuticals and was the president of global development innovations at the Sarah Cannon Research Insitute in Nashville. In addition, she was previously the director of global program management at Élan Corporation in the United Kingdom. 

Brian Alexander, Foundation's chief medical officer and senior VP, will be the interim CEO for the company. 

Jan 19, 2021

LabCorp: Deborah Ann Sesok-Pizzini

Laboratory Corporation of America appointed Deborah Ann Sesok-Pizzini chief medical officer of LabCorp Diagnostics, effective Jan. 11. She replaces Dot Adcock, who is retiring in April 2021. Sesok-Pizzini was previously at The Children's Hospital of Philadelphia where she held several positions, including patient safety officer, chief of the division of transfusion medicine, and vice-chair of pathology and laboratory medicine. She also was a professor of clinical pathology and laboratory medicine at the Perelman School of Medicine at the University of Pennsylvania.

Jan 15, 2021

Broad Institute: Eric Lander, Todd Golub

Eric Lander, founding director of the Broad Institute of the Massachusetts Institute of Technology and Harvard, has been named White House science advisor to President-elect Joseph Biden. He will specifically be nominated as director of the Office of Science and Technology Policy and serve as Presidential Science Advisor. The President-elect is designating the Presidential Science Advisor as a member of the Cabinet for the first time in history. Lander was a principal leader of the Human Genome Project, and during the Obama Administration he served as external co-chair of the President's Council of Advisors on Science and Technology.

Lander will step down from his roles at Broad, Harvard, and MIT and take an unpaid, academic leave of absence.

The Broad Institute's board has appointed Todd Golub, current chief scientific officer at the institute, as director. Golub is a founder and core member of the institute, and serves on its executive leadership team. He is also the Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute and professor of pediatrics at Harvard Medical School. Golub joined the Dana-Farber and Harvard faculty in 1997, and served as a key scientific leader of the Whitehead Institute/MIT Center for Genome Research, the precursor organization of the Broad Institute. He has also been Howard Hughes Medical Institute investigator, and has served as chair of numerous scientific advisory boards, including St. Jude Children's Research Hospital and the National Cancer Institute's scientific advisory board.

Jan 15, 2021

Agilent Technologies: Allison Ballmer

Agilent Technologies has named Allison Ballmer as senior vice president of strategy and corporate development, reporting to President and CEO Mike McMullen.

Ballmer joined Agilent in May 2018 as vice president of business development and strategy for the company's Diagnostics and Genomics business. Prior to that, she worked for more than a decade at Roche. She is currently lead director of the board of directors at Mission Bio.

Jan 15, 2021

Exact Sciences: Andrew Slavitt

In a filing with the US Securities and Exchange Commission, Exact Sciences said that Andrew Slavitt submitted his resignation as a member of the company's board on Jan. 11 after having been been appointed by President-elect Joseph Biden as a White House Senior Advisor for COVID Response. 

Jan 14, 2021

Lunaphore Technologies: Paolo Ascierto, Jérôme Galon

Swiss life sciences company Lunaphore Technologies appointed Paolo Ascierto and Jérôme Galon, who are experts in immuno-oncology, to its new Scientific Advisory Board.

Ascierto is the director of the Department of Melanoma, Cancer Immunotherapy, and Development Therapeutics at the National Tumor Institute in Naples, Italy. He is a member of the Steering Committee of the Society of Melanoma Research and the board of directors of the Society of Immunotherapy of Cancer. He is also president of the Fondazione Melanoma Onlus and the Campania Society of ImmunoTherapy of Cancer.

Galon is the director of research at INSERM (the French National Institute of Health and Medical Research) and head of the Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center in Paris. He is the cofounder of HalioDx and chairman of its scientific council.

Jan 13, 2021

C2i Genomics: Mark Oldroyd, Ravi Kandasamy, Alex Parker

C2i Genomics has appointed Mark Oldroyd as its chief business officer, Ravi Kandasamy as VP of research and development, and Alex Parker as a member of the firm's board of directors. 

Oldroyd previously served as senior VP at Tempus. Prior to Tempus, he was a senior director at Foundation Medicine.

Kandasamy most recently served as director of genomics at Bristol-Myers Squibb. In addition, he has previously served as manager of research and development in precision medicine at GlaxoSmithKline.

Parker currently serves as senior VP for clinical product strategy at Thrive Earlier Detection. Prior to Thrive, he spent more than seven years in leadership positions at Foundation Medicine. 

Jan 12, 2021

MeMed: Troy Boutelle

MeMed has appointed Troy Boutelle as VP of commercial, North America and GM, US. He will lead Haifa, Israel-based MeMed's operation in North America from Boston. He has 20 years of leadership experience at life science companies including at Eurofins-Viracor where he was its VP of sales of marketing prior to joining MeMed. He previously was commercial lead at Thermo Fisher Scientific where he led the commercial team for the Americas microbiology team.

Jan 08, 2021

Qiagen: Toraf Haag

Qiagen said Toraf Haag has been appointed to its supervisory board and audit committee. Since 2018 Haag has served as chairman of the management board of Germany-based global technology firm Voith. Before joining Voth in 2016 as chief financial officer, Haag served for more than 11 years as CFO and an executive committee member at Lonza Group.

Jan 06, 2021

DermTech: Ray Akhavan

DermTech has appointed Ray Akhavan as its general counsel. Most recently, Akhavan served as associate general counsel and chief intellectual property counsel at Ancestry. Prior to Ancestry, Akhavan served as general counsel and chief intellectual property counsel at Caris Life Sciences. He has also worked as a research biologist at the National Institutes of Health and as a patent examiner at the US Patent and Trademark Office.